Based on that, IL-23/IL-17 inflammation pathway has been proposed as a novel therapeutic target in IBD and other gastrointestinal disorders25 and interestingly, IL-17/IL-23 axis inhibition by Lactobacillus commensal bacteria showed an amelioration of DSS-induced colitis symptoms26,27, suggesting putative alternative treatment strategy. This evidence concerns the gene IL17A and colitis.